Email this article Features of immune response against influenza infection in animals vaccinated with recombinant cross-protective vaccine
- Authors: Tsybalova L.M.1, Stepanova L.A.1, Korotkov A.V.1, Shuklina M.A.1, Zaitseva M.V.1, Grishchenko V.I.1, Kotlyarov R.Y.2
-
Affiliations:
- Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
- Research Institute of Bioengineering, FIC «Fundamentals of Biotechnology» RAS
- Issue: Vol 9, No 3-4 (2019)
- Pages: 485-494
- Section: ORIGINAL ARTICLES
- URL: https://iimmun.ru/iimm/article/view/796
- DOI: https://doi.org/10.15789/2220-7619-2019-3-4-485-494
- ID: 796
Cite item
Full Text
Abstract
Generating cross-reactive vaccines aimed at targeting all human influenza A virus subtypes is among high priority tasks in contemporary vaccinology. Such vaccines will be primarily demanded during pre-pandemic period as well as used to prime some population cohorts prior to vaccination with standard vaccines containing area-relevant epidemic virus. Unlike routine approach universal vaccines do not induce a sterilizing immunity, but significantly ameliorate overt infection and probable complications. Our study was aimed at evaluating characteristics of immune response in experimental animals primed with a candidate universal vaccine challenged with sublethal influenza A virus infection. Mice were immunized intranasally with the recombinant protein FlgH2-2-4M2e containing conservative peptides derived from two influenza A virus proteins: M2 protein ectodomain and 76–130 amino acid sequence from the second hemagglutinin (HA2) subunit genetically linked to bacterial flagellin protein, which is a ligand for Toll-like receptor 5 (TLR5). Control mice received saline. Two weeks after immunization, mice from both groups were infected with a sublethal dose of A/Aichi/2/68 AN3N2 influenza virus strain. Level of immunoglobulins G and A in the blood sera and bronchoalveolar lavages (BAL) were determined two weeks after immunization and 1 month post infection. Percentage of lung CD4+ T and CD4+ Tem (CD44+CD62L–) cells secreting cytokines TNFα, IFNγ, IL-2 was determined. Immunized vs. control mice responded to sublethal infection with the influenza virus by insignificant weight loss and more pronounced production of vaccine peptide-specific (M2e and aa76–130 HA2) and pan-influenza A/Aichi/2/68 virus IgG and A in the blood sera and BAL. After challenge the number of CD4+ T cells secreting cytokines TNFα and/or IL-2 in immunized mice significantly exceeded counterpart T cells in unimmunized animals that was true for both CD4+T and CD4+ Tem cells. Memory CD4+ T cells were previously shown to play a key role in the prime-boost event and heterosubtypic immune response. Thus, we were able to demonstrate a priming effect for recombinant cross-protective vaccine used in our experiment.
About the authors
L. M. Tsybalova
Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
Author for correspondence.
Email: sovet@influenza.spb.ru
PhD, MD (Medicine), Head of the Department of Vaccinology, Head of the Laboratory of Influenza Vaccines, Advisor to the Director,
197376, St. Petersburg, Professora Popova str., 15/17
Russian FederationL. A. Stepanova
Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD (Biology), Leading Researcher, Laboratory of Influenza Vaccines,
St. Petersburg
Russian FederationA. V. Korotkov
Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
Researcher, Laboratory of Influenza Vaccines,
St. Petersburg
M. A. Shuklina
Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
Junior Researcher, Laboratory for Influenza Vaccines,
St. Petersburg
Russian FederationM. V. Zaitseva
Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
Junior Researcher, Laboratory of Influenza Vaccines,
St. Petersburg
Russian FederationV. I. Grishchenko
Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
Junior Researcher, Laboratory of Influenza Vaccines,
St. Petersburg
Russian FederationR. Yu. Kotlyarov
Research Institute of Bioengineering, FIC «Fundamentals of Biotechnology» RAS
Email: fake@neicon.ru
PhD (Biology), Researcher, Department of Molecular Biology of Microorganisms,
Moscow
Russian FederationReferences
- Степанова Л.А., Котляров Р.Ю., Шуклина М.А., Блохина Е.А., Сергеева М.В., Потапчук М.В., Ковалева А.А., Равин Н.В., Цыбалова Л.М. Влияние порядка присоединения фрагментов НА2 и М2е вирусов гриппа A к флагеллину на свойства рекомбинантных белков // Acta Naturae. 2018. Т. 10, № 1 (36). C. 90–100.
- Atsmon J., Caraco Y., Ziv-Sefer S., Shaikevich D., Abramov E., Volokhov I., Bruzil S., Haima K.Y., Gottlieb T., Ben-Yedidia T. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine, 2014, vol. 32, no. 44, pp. 5816–5823. doi: 10.1016/j.vaccine.2014.08.031
- Bates J.T., Honko A.N., Graff A.H., Kock N., Mizel S.B. Mucosal adjuvant activity of flagellin in aged mice. Mech. Ageing Dev., 2008, vol. 129, pp. 271–281. doi: 10.1016/j.mad.2008.01.009
- Chen S., Zheng D., Li C., Zhang W., Xu W., Liu X., Fang F., Chen Z. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. Biomed. Res. Int., 2015: 901817. doi: 10.1155/2015/901817
- Cuadros C., Lopez-Hernandez F.G., Dominguez A.L., McClelland M., Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect. Immun., 2004, vol. 72, no. 5, pp. 2810–2816.
- Cunningham A.F., Khan M., Ball J., Toellner K.M., Serre K., Mohr E. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur. J. Immunol., 2004, vol. 34, pp. 2986–2995.
- De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., Vandekerckhove J., Fiers W., Saelens X. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J. Biol. Chem., 2008, vol. 283 (17), pp. 11382–11387. doi: 10.1074/jbc.M800650200
- Delaney K.N., Phipps J.P., Johnson J.B., Mizel S.B. A reombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol., 2010, vol. 23, pp. 201–210. doi: 10.1089/vim.2009.0107
- Deng L., Ibañez L.I., Van den Bossche V., Roose K., Youssef S.A., de Bruin A., Fiers W., Saelens X. Protection against influenza A virus challenge with M2e-displaying filamentous Escherichia coli phages. PLoS One, 2015. doi: 10.1371/journal.pone.0126650
- El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol., 2011, vol. 186, pp. 1022–1031. doi: 10.4049/jimmunol.0902147
- Eliasson D.G., Omokanye A., Schön K., Wenzel U.A., Bernasconi V., Bemark M., Kolpe A., El Bakkouri K., Ysenbaert T., Deng L., Fiers W., Saelens X., Lycke N. M2e tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunol., 2017, vol. 11, pp. 273–289. doi: 10.1038/mi.2017.14
- Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., Subbarao K. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J. Immunol., 1997, vol. 158, no. 3, pp. 1222–1230.
- Hazenbos W.L., Gessner J.E., Hofhuis F.M. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity, 1996, vol. 5, pp. 181–188.
- Jegerlehner A. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol., 2004, vol. 172, pp. 5598–5605.
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, vol. 227, pp. 680–685.
- McKinstry К.К., Strutt T.M., Kuang Yi, Brown D.M., Sell S., Dutton R.W., Swain S.L. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J. Clin. Invest., 2012, vol. 122, no. 8, pp. 2847–2856. doi: 10.1172/JCI63689
- Mozdzanovska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virology J., 2007, vol. 4: 118.
- Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin G subclasses activity through selective Fc receptor binding. Science, 2005, vol. 310, pp. 1510–1512.
- Scorza B.F., Tsvetnitsky V., Donnelly J.J. Universal influenza vaccines: Shifting to better vaccines. Vaccine, 2016, vol. 34, no. 26, pp. 2926–2933. doi: 10.1016/j.vaccine.2016.03.085
- Strutt T.M., McKinstry K.K., Dibble J.P., Winchell C., Kuang Y., Curtis J.D., Huston G., Dutton R.W., Swain S.L. Memory CD4+ T cells induce innate responses independently of pathogen. Nat. Med., 2010, vol. 16, no. 5, pp. 558–564. doi: 10.1038/ nm.2142
- Sun K., Ye J., Perez D.R., Metzger D.W. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J. Immunol., 2011, vol. 186, no. 2, pp. 987–993. doi: 10.4049/jimmunol.1002664
- Swain S.L., McKinstry K.K., Strutt T.M. Expanding roles for CD4(+) T cells in immunity to viruses. Nat. Rev. Immunol., 2012, vol. 12, no. 2, pp. 136–148. doi: 10.1038/nri3152
- Tsybalova L.M., Stepanova L.A., Shuklina M.A., Mardanova E.S., Kotlyarov R.Y., Potapchuk M.V., Petrov S.A., Blokhina E.A., Ravin N.V. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine. PLoS One, 2018, vol. 13, no. 8: e0201429. doi: 10.1371/journal.pone.0201429
- Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol., 1988, vol. 62, no. 8, pp. 2762–2772.
- Zens K.D., Farber D.L. Memory CD4 T cells in influenza. Curr. Top. Microbiol. Immunol., 2015, vol. 386, pp. 399–421. doi: 10.1007/82_2014_401
- Zhong W., Reed C., Blair P.J., Katz J.M., Hancock K. Influenza Serology Working Group. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J. Infect. Dis., 2014, vol. 209, no. 7, pp. 986–994. doi: 10.1093/infdis/jit811
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).